Overview of Dr. Razavi
Dr. Pedram Razavi is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Tehran University of Medical Sciences School of Medicine and has been in practice 16 years. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
300 East 66th Street
Floors 1 - 4
New York, NY 10065
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2010 - 2013
University of Southern CaliforniaPhD, Cancer epidemiology , 2005 - 2009- University of Southern CaliforniaMPH, 2005 - 2007
Tehran University of Medical Sciences School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2013 - Present
FL State Medical License 2021 - Present
NY State Medical License 2013 - 2026
NJ State Medical License 2020 - 2025
Publications & Presentations
PubMed
- Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer.Mark Zucker, Maria A Perry, Samuel I Gould, Arielle Elkrief, Anton Safonov
Cell. 2024-12-12 - 1 citationsAutomated real-world data integration improves cancer outcome prediction.Justin Jee, Christopher Fong, Karl Pichotta, Thinh Ngoc Tran, Anisha Luthra
Nature. 2024-12-01 - 4 citationsLong-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.Rei Kudo, Anton Safonov, Catherine Jones, Enrico Moiso, Jonathan R Dry
Cancer Cell. 2024-11-11
Journal Articles
- Accuracy of Magnetic Resonance Imaging–Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant ChemotherapyElizabeth J Sutton, Lior Z Braunstein, Yolanda Bryce, Jill S Gluskin, Pedram Razavi, JAMA Network Open
Lectures
- A deep dive into the cfDNA pool: Clonal hematopoiesis as a major source of somatic mutationsAACR Advances in Liquid Biopsies, Miami - 1/15/2020
- The Genomic Landscape of Endocrine-Resistant Metastatic Breast CancerSan Antonio Breast Cancer Symposium - 12/10/2019
- Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors.2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Press Mentions
Multimodal Machine Learning Model Forecasts CDK4/6 Inhibitor Response in Metastatic Breast CancerDecember 18th, 2024- Predicting Treatment Response in Patients with HR-Positive, HER2-Negative Breast CancerDecember 16th, 2024
- Year in Review Session Summarizes Important Breast Cancer Takeaways from 2024December 15th, 2024
- Join now to see all
Professional Memberships
- Associate
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
